Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 study of ZN-c3 in patients with advanced solid tumors

Next Previous
X
Search
Trial Profile

A Phase 1/2 study of ZN-c3 in patients with advanced solid tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azenosertib (Primary)
  • Indications Carcinoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Uterine cancer
  • Focus Therapeutic Use
  • Sponsors Zentalis Pharmaceuticals

    • Most Recent Events

    • 06 Jun 2023 According to Zentalis Pharmaceuticals media release, Company plans to update efficacy data from Phase 1 monotherapy dose optimization study and provide program timeline updates for three azenosertib Phase 2 monotherapy trials currently enrolling patients at the RP2D in the second half of 2023.
    • 06 Jun 2023 According to Zentalis Pharmaceuticals media release, Company will host a webcast today at 8:00 a.m. ET to review the azenosertib Phase 1 monotherapy data supporting dose selection, as well as the positive azenosertib plus chemotherapy Phase 1b combination data presented at the 2023 ASCO Annual Meeting.
    • 06 Jun 2023 Results of 127 patient data of phase 1 dose optimization as of April 24, 2023, presented in a Zentalis Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top